GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Short-Term Capital Lease Obligation

CanSino Biologics (SHSE:688185) Short-Term Capital Lease Obligation : ¥9.3 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics Short-Term Capital Lease Obligation?

CanSino Biologics's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥9.3 Mil.

CanSino Biologics's quarterly Short-Term Capital Lease Obligation declined from Dec. 2023 (¥64.6 Mil) to Mar. 2024 (¥0.0 Mil) but then increased from Mar. 2024 (¥0.0 Mil) to Jun. 2024 (¥9.3 Mil).

CanSino Biologics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (¥31.2 Mil) to Dec. 2022 (¥48.8 Mil) and increased from Dec. 2022 (¥48.8 Mil) to Dec. 2023 (¥64.6 Mil).

CanSino Biologics Short-Term Capital Lease Obligation Historical Data

The historical data trend for CanSino Biologics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Short-Term Capital Lease Obligation Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial 8.80 8.59 31.18 48.76 64.63

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.34 - 64.63 - 9.27

CanSino Biologics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

CanSino Biologics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Short-Term Capital Lease Obligation
Comparable Companies
HKSE:02005 HKSE:03933 HKSE:00512 HKSE:03613 HKSE:01349 HKSE:02096 HKSE:01558 HKSE:00570 HKSE:06600 HKSE:00460 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CASBF:USA 06185:Hong Kong CJH:Germany
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

CanSino Biologics Headlines

No Headlines